GLP-1 Market
LLY $1283.66 ▲ +3.5% NVO $39.35 ▲ +2.4% PFE $30.11 ▲ +2.3% VKTX $26.71 ▲ +6.6% KLRA $12.89 ▲ +12.8% GPCR $22.88 ▲ +4.0% RHHBY $59.11 ▲ +3.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Zodasiran

Company
Arrowhead Pharmaceuticals
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 21, 2026

Find a Clinical Trial Near Me

See recruiting studies for Zodasiran and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07473843

    Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia

    Not yet reported Arrowhead Pharmaceuticals 10 participants Est. completion 2028-08 2 sites Stand-alone
    Other conditions: Homozygous Familial Hypercholesterolemia
    View official trial listing →
  • Completed NCT NCT03747224

    Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients

    Not yet reported Arrowhead Pharmaceuticals 93 participants Est. completion 2021-05-17 6 sites Stand-alone
    Other conditions: Dyslipidemias, Familial Hypercholesterolemia, Hypertriglyceridemia
    View official trial listing →
  • Completed NCT NCT04832971

    Study of ARO-ANG3 in Adults With Mixed Dyslipidemia

    Not yet reported Arrowhead Pharmaceuticals 204 participants Est. completion 2024-09-25 24 sites Stand-alone
    Other conditions: Mixed Dyslipidemia
    View official trial listing →
  • Terminated NCT NCT05217667

    Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)

    Not yet reported Arrowhead Pharmaceuticals 18 participants Est. completion 2025-11-13 7 sites Stand-alone
    Other conditions: Homozygous Familial Hypercholesterolemia
    View official trial listing →
  • Active, not recruiting NCT NCT06712771

    A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients

    Not yet reported Visirna Therapeutics HK Limited 46 participants Est. completion 2027-12-30 1 site
    Other conditions: Homozygous Familial Hypercholesterolemia (HoFH)
    View official trial listing →
  • Active, not recruiting NCT NCT07037771

    A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

    Not yet reported Arrowhead Pharmaceuticals 70 participants Est. completion 2027-08-20 43 sites Stand-alone
    Other conditions: Homozygous Familial Hypercholesterolemia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Zodasiran, ARO-ANG3

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.